• 患者服务: 与癌共舞小助手
  • 微信号: yagw_help22

QQ登录

只需一步,快速开始

开启左侧

我父亲肺鳞癌的治疗贴(2014年3月1日驾鹤西去)

    [复制链接]
1201323 1620 老马 发表于 2011-10-27 08:05:18 | 置顶 |
老马  博士一年级 发表于 2012-4-27 18:50:42 | 显示全部楼层 来自: 浙江温州
Pooled Analysis of S-1 Trials in Non-Small Cell Lung Cancer According to Histological Type  \% a; W+ |) [+ q6 q
NOBUYUKI YAMAMOTO1, TAKEHARU YAMANAKA2, YUKITO ICHINOSE3, KAORU KUBOTA4, HIROSHI SAKAI5, AKIHIKO GEMMA6, NAGAHIRO SAIJO7, MASAHIRO FUKUOKA8 and HISANOBU NIITANI9
% v# [5 M' `7 Z* j4 [  J  Z+ Author Affiliations5 A) C6 H( o0 z  q$ d
) P% C; f- p+ h7 a, J8 f6 b8 ^* i
1Division of Thoracic Oncology, Shizuoka Cancer Center, Shizuoka 411-8777, Japan
: U, J. u4 s& J0 E+ o2Cancer Biostatistics Laboratory, Institute for Clinical Research, National Kyushu Cancer Center, Fukuoka 811-1395, Japan
' J* H6 G8 c4 T! r: d8 a  _5 }3Department of Thoracic Oncology, National Kyushu Cancer Center, Fukuoka 811-1395, Japan ' w3 N$ l" Q* J9 i  s$ w$ _
4Division of Thoracic Oncology, National Cancer Center Hospital, Tokyo 104-0045, Japan
9 B$ t4 K1 I5 r/ s1 X5Division of Thoracic Oncology, Saitama Cancer Center, Saitama 362-0806, Japan + [" i' ?* M7 S# v, o% B7 j
6Division of Pulmonary Medicine, Infectious Diseases, and Oncology Department of Internal Medicine, Nippon Medical School, Tokyo 113-8603, Japan
8 F, A. _# c" t/ `7 y" `# [7Kinki University School of Medicine, Osaka 589-8511, Japan
+ v  f8 E6 N# m* M& O8 c) n. I8Izumi Municipal Hospital, Osaka 594-0071, Japan   i/ R1 G/ d' u8 p1 L7 x; o7 G
9Tokyo Cooperative Oncology Group, Tokyo 105-0013, Japan ; d% \; j9 Q/ W) K
Correspondence to: Nobuyuki Yamamoto, Division of Thoracic Oncology, Shizuoka Cancer Center, 1007 Shimonagakubo, Nagaizumi-cho, Sunto-gun, Shizuoka 411-8777, Japan. Tel: +81 559895222, Fax: +81 559895783, e-mail: n.yamamoto@scchr.jp " e# H7 M" v: X; {- V; R/ W, M
AbstractBackground: The antimetabolic agent S-1 inhibits thymidylate synthase similar to pemetrexed, but through a different mechanism of action. Whether the antitumour activity of S-1 depends on histological type remains unclear. We analysed pooled data from 2 phase II clinical studies of cisplatin and S-1 in patients with previously untreated advanced non-small cell lung cancer. Patients and Methods: We comprised 110 patients with stage IIIB or IV non–small cell lung cancer. Univariate and multivariate analyses were performed to determine the effects of histological type on progression-free survival and response rates. Results: On pooled analysis of the data, according to histological type, median progression-free survival was 3.8 months in patients with squamous cell carcinoma and 4.4 months in those with non-squamous cell carcinoma. Both analyses showed that progression-free survival and response rate did not differ significantly. Conclusion: Unlike molecular targeted agents and pemetrexed, a combination of cisplatin and S-1 may be no difference in response according to histological type. $ ^2 H# A/ }9 s+ n4 K* |

6 A% U- E) w( T0 K6 o5 G& [
个人公众号:treeofhope
老马  博士一年级 发表于 2012-4-27 18:52:43 | 显示全部楼层 来自: 浙江温州
S-1 monotherapy for previously treated non-small cell lung cancer: A retrospective analysis by age and histopathological type 3 n6 w! ~+ l% h0 ^/ z4 ?& r- }3 y  a
2 s; b$ Z, d: j+ n( I5 K
Authors: Yuki Tomita, Tetsuya Oguri, Osamu Takakuwa, Makoto Nakao, Eiji Kunii, Takehiro  Uemura, Hiroaki Ozasa, Mikinori Miyazaki, Ken Maeno, Shigeki Sato : J9 ^+ d; t. R2 w6 P2 o$ r: i- p; v

: I3 A9 H+ R3 u' S# hAffiliations: Department of Medical Oncology and Immunology, Nagoya City University Graduate School of Medical Sciences, Mizuho-cho, Mizuho-ku, Nagoya, Aichi 467-8601, Japan  
/ T: ^, A) m+ p3 x3 P; u* V& n( L& R' e) s, ?' b9 ~7 O, ]7 k  [
Published online on: Thursday, December 1, 2011
7 ~0 o9 z7 c9 b9 S/ }0 N# d/ z. s0 s8 L% P: R  Y* P! e; c
Doi: 10.3892/ol.2011.507 & i' a7 ~1 D4 n6 a- n( L: V
/ S+ ~& {' M" M6 }" N9 j
Pages: 405-410 6 Y$ s7 @7 l( n/ H/ o4 `- p5 h8 L

) \  U8 E! H: u+ S" K7 rAbstract:+ i* `  x5 J, r; Q- P6 V
S-1, an oral fluoropyrimidine derivative, has been approved for the treatment of non-small cell lung cancer (NSCLC) in Japan. In the present study, the efficacy and safety of S-1 monotherapy for elderly patients with previously treated NSCLC were retrospectively evaluated, and the efficacy of S-1 monotherapy was compared by histopathological type. This retrospective study included 54 patients with advanced or recurrent NSCLC who had received S-1 monotherapy following the failure of previous chemotherapy regimens at our institutes. Patient outcomes were compared based on their age and histopathological type. S-1 was administered orally, twice daily, while the duration and interval were modified according to the medical condition of each patient. The default delivery schedule, the mean number of S-1 cycles, did not differ significantly between the two age groups (<70 and ≥70 years). The rate of therapy discontinuation, schedule modification or dose reduction due to intolerable toxicities or patient refusal was relatively frequent in the older group (40.7 and 55.6% for ages <70 and ≥70 years, respectively; p=0.414), and the incidence of grade 3 anemia was relatively high in the older group (3.7 and 18.5%, respectively; p=0.192). The response rates (13.0 and 4.8%, respectively; p=0.609) and disease control rates (39.1 and 33.3%, respectively; p=0.761) did not differ significantly between the two age groups. According to histopathological type, the disease control rate was significantly higher in adenocarcinoma (57.9%) compared to non-adenocarcinoma (20.0%, p=0.013). Thus, S-1 monotherapy may be equally effective and tolerated in patients <70 years and those ≥70 years. Additionally, adenocarcinoma may have a higher disease control rate than non-adenocarcinoma.
8 k8 p/ s& Y7 Q7 Z" C- }
! H1 l* a, G8 a$ p
个人公众号:treeofhope
老马  博士一年级 发表于 2012-4-27 18:57:27 | 显示全部楼层 来自: 浙江温州
Thymidylate synthase (TS) gene expression in primary lung cancer patients: a large-scale study in Japanese population/ t) g, u! ^* e" P% M) P* R0 a
F. Tanaka1,*, H. Wada2, Y. Fukui3 and M. Fukushima3
- F  D0 Q) X; x- ~1 ~8 O+ B) c7 ?+ Author Affiliations4 ?# T- y0 c  z# ?6 ^; U
1Second Department of Surgery, University of Environmental and Occupational Health, Kitakakyushu ! [8 Q+ C) f3 ]& _* }( T' _
2Department of Thoracic Surgery, Kyoto University, Kyoto
% P8 e  `" l0 q$ V3Tokushima Research Center, Taiho Pharmaceutical Co. Ltd, Tokushima, Japan 9 q: C9 [& j; y* |
&#8629;*Correspondence to: Dr F. Tanaka, Second Department of Surgery, University of Environmental and Occupational Health, 1-1 Isegaoka, Yahata-nishi, Kitakakyushu, 807-8555, Japan. Tel: +81-93-891-7442; Fax: +81-93-692-4004; E-mail: ftanaka@med.uoeh-u.ac.jp : d2 V& Z4 e1 _( V' t" C+ y* E
Received September 3, 2010. 6 t! u. \) B; q2 }& |/ I4 w
Revision received November 11, 2010. 7 Z' `( G8 |3 j- M% L1 q& a9 Z" C* O
Accepted November 17, 2010. 4 T1 {: z' [( |) ], n; {
Abstract! j! N: |6 i% F8 o5 a
Background: Previous small-sized studies showed lower thymidylate synthase (TS) expression in adenocarcinoma of the lung, which may explain higher antitumor activity of TS-inhibiting agents such as pemetrexed.
+ j* C, S+ S8 x) u( EPatients and methods: To quantitatively measure TS gene expression in a large-scale Japanese population (n = 2621) with primary lung cancer, laser-captured microdissected sections were cut from primary tumors, surrounding normal lung tissues and involved nodes.
1 t* {9 J0 w3 c. [. Y+ v4 U0 _Results: TS gene expression level in primary tumor was significantly higher than that in normal lung tissue (mean TS/β-actin, 3.4 and 1.0, respectively; P < 0.01), and TS gene expression level was further higher in involved node (mean TS/β-actin, 7.7; P < 0.01). Analyses of TS gene expression levels in primary tumor according to histologic cell type revealed that small-cell carcinoma showed highest TS expression (mean TS/β-actin, 13.8) and that squamous cell carcinoma showed higher TS expression as compared with adenocarcinoma (mean TS/β-actin, 4.3 and 2.3, respectively; P < 0.01); TS gene expression was significantly increased along with a decrease in the grade of tumor cell differentiation. There was no significant difference in TS gene expression according to any other patient characteristics including tumor progression.
4 m# l  i( o1 A" mConclusion: Lower TS expression in adenocarcinoma of the lung was confirmed in a large-scale study.
4 w: j6 M& o" B9 Z0 L2 L- o
个人公众号:treeofhope
走在异乡  高中一年级 发表于 2012-4-28 00:30:22 | 显示全部楼层 来自: 四川成都
一直关注老马的帖子,前方的指明灯。祝福你爸好疗效
累计签到:1 天
连续签到:1 天
[LV.1]初来乍到
baiselianyi  初中二年级 发表于 2012-4-28 10:24:44 | 显示全部楼层 来自: 浙江台州
一直得到老马帮助,祝福老马爸爸
老马  博士一年级 发表于 2012-4-28 18:00:37 | 显示全部楼层 来自: 浙江温州
26日吃了12片地米(0.75mg一片),27日吃了22片地米(0.75mg 一片),28日吃了12片地米(0.75mg一片),都分二次吃。
6 p$ {" E4 S8 M7 D8 d; V今天为止没有任何反应,每天吃VC,VB2,还有漱口水,就怕口腔溃疡。
个人公众号:treeofhope
bishop_cn  大学一年级 发表于 2012-4-28 23:16:11 | 显示全部楼层 来自: 中国
副作用如何,单药反应很小吧?
% j( H/ i- f! o* ]  f8 X
老马  博士一年级 发表于 2012-4-29 00:20:00 | 显示全部楼层 来自: 浙江温州
LUX-Lung 8: A Phase III Trial of Afatinib (BIBW 2992) Versus Erlotinib for the Treatment of Squamous Cell Lung Cancer After at Least One Prior Platinum Based Chemotherapy
: m% h0 z. L- e& X9 w& S. _http://clinicaltrials.gov/ct2/show/NCT01523587
3 X/ r1 X9 }/ f. e" q
2 k- ^* Y! H. o% GBIBW 2992 Plus Simvastatin vs. BIBW 2992 in Previously Treated Patients With Advanced Non-adenocarcinomatous NSCLC  Z8 r( D- Q7 K) _4 Z
http://clinicaltrials.gov/ct2/show/NCT01156545
个人公众号:treeofhope
老马  博士一年级 发表于 2012-4-29 20:53:58 | 显示全部楼层 来自: 浙江温州
本帖最后由 老马 于 2012-4-30 09:33 编辑 * ~1 Q( q: f2 ]! s

1 O8 D' H% e! z从4月24日开始到4月28日,打了5天的舒普深(注射用头孢哌酮钠舒巴坦钠),效果非常好。
5 Y! f8 ]7 _& x/ C* g# O至今为止,未出现化疗副作用。
个人公众号:treeofhope
英雄武松  大学四年级 发表于 2012-4-30 01:37:05 | 显示全部楼层 来自: 哈萨克斯坦
老马 发表于 2012-4-29 20:53
: n' {7 U( e% B/ _. F2 {( {" ?. o' B6 l从4月24日开始到4月28日,打了5天的打了5天舒普深(注射用头孢哌酮钠舒巴坦钠),效果非常好。
% u" v0 C* @& Q4 J2 a至今为止,未出 ...
- j4 b/ r8 |& l, ~" X
没有副作用是第一追求,效果显著是第二追求。& Y7 |1 J1 Y. v$ W
不错。

发表回复

您需要登录后才可以回帖 登录 | 立即注册

本版积分规则

  • 回复
  • 转播
  • 评分
  • 分享
帮助中心
网友中心
购买须知
支付方式
服务支持
资源下载
售后服务
定制流程
关于我们
关于我们
友情链接
联系我们
关注我们
官方微博
官方空间
微信公号
快速回复 返回顶部 返回列表